Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

BeiGene

Global X China Biotech Innovation ETF

Global X MSCI China Health Care ETF

KraneShares MSCI All China Health Care Index ETF

Roche Holding AG

Healthcare was the second-best performing sector in China in 2020.

China Healthcare: A Rediscovered Sector Keeps Its Momentum

Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie Biosciences. These compounds target fibroblast activation protein or FAP, a cell surface protein found in low levels in healthy tissue but found in high levels in common cancers.

Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal

The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.

Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS

Johnson & Johnson

Johnson & Johnson's (NYSE:JNJ) 2020 revenue topped all pharmaceutical companies, according to rankings published by Fierce Pharma.

Johnson & Johnson, Roche and Novartis Top in Pharma Sales

Genmab - ADR

Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis. The company is developing and marketing the product under a license agreement with Genmab A/S (NASDAQ: GMAB).

Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc. The FAP assets were originally developed at the University of Heidelberg. The agreement also includes co-exclusive rights for Novartis to develop imaging applications for these assets.

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Shares in Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHIF) (FRA:VP2) headed north on Monday as it struck a deal with Novartis Pharmaceuticals to commercialize two Health Canada approved asthma therapies. Under the agreement, Valeo will be responsible for medical and commercial activities for Enerzair Breezhaler and Atectura Breezhaler for an initial eight years, positioning it as one of the leading Canadian respiratory companies.

Valeo Pharma shares get a boost as it unveils deal with Novartis on two Health Canada approved asthma therapies

Novartis on Wednesday had to correct comments made by Chairman Joerg Reinhardt to a Swiss newspaper, because his portrayal of conduct that led to a $678 million U.S. settlement over kickbacks last year risked violating the agreement.

Novartis corrects chairman's comments about kickbacks case

Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.

Novartis (NVS) Posts Positive Data From Prostate Cancer Study

Novartis AG (NYSE: NVS) says that its Phase 3 VISION study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients. Details were not disclosed.

Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study

Basel, March, 23, 2021 — Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone. The trial met both primary endpoints of overall survival and radiographic progression-free survival1, helping to move closer the ambition of becoming the targeted treatment for >80% of patients with advanced prostate cancer. The safety profile was consistent with data reported in previous clinical studies1. Results from the VISION trial will be presented at an upcoming medical meeting and included in US and EU regulatory submissions.

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective May 15, 2021. Ms. Hale will be based in Basel, Switzerland and succeeds Shannon Klinger. Tom Kendris will continue as Chief Legal Officer ad interim until Ms. Hale joins.

Novartis appoints Karen Hale as Chief Legal Officer

Snowflake

Digging into the popular investors' portfolios teaches us to look beyond Wall Street labels.

1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should

Puma Biotechnology

Celcuity

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clinical trial. The open-label Phase 2 trial will evaluate the efficacy and safety of two targeted therapies, Novartis' Tabrecta, a c-Met inhibitor, and Puma's Nerlynx, a pan-HER inhibitor, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuity's CELsignia Multi-Pathway Activity Test.

Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast Cancer

Holding Edgewell Personal Care has been a painful experience for a number of years, but this might be coming to an end.

Novartis Is Almost A Dividend Aristocrat And It's A Good Time To Consider It

ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021 Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3 Clinical trial includes an interim analysis after 300 patients Separately, a global Phase 2-3 study in adults with mild to moderate symptoms is planned to be initiated in Q2 2021 Initial Phase 1 data support safety, tolerability and 2-3 week half-life of ensovibep ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3 randomized, controlled clinical trial as part of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. The trial, ACTIV-3, is designed to evaluate the safety and efficacy of various therapies for the treatment of adults hospitalized with a COVID-19 diagnosis.

Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial

Ebang International Holdings

Novavax

Seelos Therapeutics

AT&T

The stock market has some major movers as noon rolls around on Friday and InvestorPlace is looking at what stocks are up today. The post Midday Market Update: What Stocks Are Up Today?

Midday Market Update: What Stocks Are Up Today?

argenx

Biohaven Pharmaceutical Hld

BioMarin Pharmaceutical

Mirati Therapeutics

Novo Nordisk

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

7 Pharmaceutical Stocks Working on Their Next Blockbuster

NLS Pharma (NLSP) stock is taking off on Friday after announcing an exclusive license agreement with Novartis (NVS) for mazindol data. The post NLSP Stock: The Big Deal News That Has NLS Pharma Rocketing Nearly 100% Today appeared first on InvestorPlace.

NLSP Stock: The Big Deal News That Has NLS Pharma Rocketing Nearly 100% Today

NLS Pharmaceutics AG (NASDAQ: NLSP) stock has more than doubled in reaction to a License Agreement with Novartis Pharma AG, a unit of Novartis AG (NYSE: NVS), wherein NLS secured an exclusive license to Sanorex (mazindol) in the U.S. Sandoz developed Sanorex as an immediate-release obesity drug designed to shed pounds fast.

NLS Pharmaceutics Stock Surges On Obesity Drug Licensing Pact With Novartis Pharma

DraftKings

H&R Block

ACADIA Pharma

bluebird bio

Barnes & Noble Education

Pulmonx

SNDL Inc.

Vermilion Energy

With the trading day more than halfway over, the broad markets were pushing higher yet again.

DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls

Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.

Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint

Novartis AG (NYSE: NVS) reported data from the Phase 3 CANOPY-2 study evaluating canakinumab (ACZ885) in advanced or metastatic non-small cell lung cancer (NSCLC). The study did not meet the primary endpoint of overall survival (OS).

Novartis' Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial

Molecular Partners AG (OTCMKTS: MLLCF) and its collaborator Novartis AG (NYSE: NVS) have announced initial results from the ongoing Phase 1 study of its COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers. In two cohorts of a single infusion of either 3mg or 9mg per kilogram body weight dosing, ensovibep was seen to be safe and well-tolerated.

Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study

Initial findings show ensovibep to be safe and well tolerated with no significant adverse events Predictable exposure seen post administration, confirming the expected half-life of 2‑3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /  March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers. In the placebo-controlled phase 1 study, healthy volunteers were randomized 3:1 to receive an infusion of ensovibep, or placebo, respectively.

Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers

News for Novartis Stock (NVS)